Our very own Dr. John Abrahams would like to announce some exciting news. In 2005 Dr. Abrahams, along with one other, founded Endomedix, Inc. The firm was focused on the development of biopolymer chemistry to produce solutions that would form hydrogel devices to use for various indications. Dr. Abrahams currently sits as a member of the Board of Directors and provides valuable insight and guidance; especially related to brain tumor and spine surgery. He delivers experience and expertise from his work with the Brain Tumor Research Foundation. On October 11, 2019, Endomedix, Inc. joined the US Army Medical Research Groups through a CRADA for an Ocular Projectile Battlefield Trauma Project. Please read on for the specific details.
Endomedix, Inc. recently announced that it has entered into a Cooperative Research and Development Agreement or CRADA with the U.S. Army Institute of Surgical Research (USAISR) and the U.S. Army Medical Materiel Development Activity (USAMMDA). The CRADA will address a specific topic, "Ocular Projectile Battlefield Trauma Project,” an unsolved emergency medical treatment problem for warfighters injured during battle.
“This project is a result of a meeting and subsequent discussions that we had with U.S. Army representatives during which we discussed several potential programs,” noted Richard Russo, Endomedix CEO. “Endomedix has developed a novel polysaccharide chemistry platform that will be used to develop a series of differential biosurgical devices, ranging from game changing absorbable hemostats to specialty wound treatments to tissue sealants and sustained released devices. The ocular projectile battlefield trauma project is the first result of our discussions with the U.S. Army groups.”
The U.S. Army is interested in developing a battlefield treatment for high speed ocular puncture wounds with irregular injury patterns. The goal is to develop a treatment that can be applied in the field to injured soldiers to protect the injured eye and surrounding tissue until the injured warfighter can be transported to a hospital for surgery or other treatment by an ophthalmologist. The project will start by assessing the feasibility of using the Endomedix’s current formulation to address a series of specific conditions. Testing will be conducted by USAISR in San Antonio and will include testing with porcine cadaveric eyes. Endomedix will supply material samples for evaluation and expertise in several areas.
The principal thrust of the Endomedix development program is the development of an absorbable hemostat for use in brain and spinal surgeries, to be followed by other biosurgical applications and other military and healthcare applications. The CRADA will piggyback on the development activities for the absorbable hemostat project.
About Endomedix, Inc.
Endomedix is a private biotechnology company that has developed a patented platform technology that it will use to develop a series of biosurgery products. The first products from this platform will be a series of absorbable hemostats for surgical, military and first responder applications. The Company is also planning a project to assess the utility of its technology to manage ocular battlefield trauma. Subsequent developments using its technology platform will include a series of tissue sealant, sustained release drug delivery and tissue engineering devices. Endomedix, Inc. is located at 1 Normal Avenue, Center for Environmental and Life Sciences, Suite 404, Montclair, New Jersey 07043. For more information, contact Richard Russo, CEO, via email at email@example.com.